158941-22-1

Basic information

• Product Name: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, ethyl ester
• Synonyms: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, ethyl ester;ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylate
• CAS NO: 158941-22-1
• Molecular Formula: C₁₉H₁₅Cl₃N₂O₂
• Molecular Weight: 409.6936
• Mol File: 158941-22-1.mol
• Article Data: 38

Chemical Properties

• Melting Point: 120-121 °C
• Boiling Point: 522.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: -2.88±0.10(Predicted)
• CAS DataBase Reference: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, ethyl ester(158941-22-1)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, ethyl ester(158941-22-1)

Safety Data

• Hazardous Substances Data: 158941-22-1(Hazardous Substances Data)

Usage

Chemical class

Pyrazole compounds

Explanation

The compound belongs to the pyrazole class of compounds, which is a group of organic compounds containing a five-membered ring with one nitrogen atom.

Explanation

This represents the composition of the compound, with 20 carbon atoms, 15 hydrogen atoms, 3 chlorine atoms, 2 nitrogen atoms, and 2 oxygen atoms.
3. Ethyl ester derivative

Explanation

The compound is derived from ethyl alcohol, indicating the presence of an ester functional group in its structure.
4. Common use in pharmaceutical industry

Explanation

Due to its unique structure and properties, the compound is commonly used in the pharmaceutical industry for potential drug development and other medical applications.
5. Biological activity

Explanation

The compound's structure suggests that it may have biological activity, which could make it suitable for use as a drug or in other medical applications.
6. Purity and concentration-dependent properties

Explanation

The specific properties and potential uses of this chemical may vary depending on its purity and concentration, which can affect its effectiveness and safety in various applications.

Upstream product

• 6285-05-8 4'-chloropropiophenone 
• 1012314-40-7 ethyl 4-(4-chlorophenyl)-3-methyl-4-oxydo-2-oxobuten-3-oate lithium salt 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 95-92-1 oxalic acid diethyl ester 
• 759-65-9 diethyl oxalpropionate 
• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 169544-41-6 4-(4-chlorophenyl)-3-methyl-2,4-dioxobutyric acid ethyl ester 
• 170937-37-8 4-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyric acid ethyl ester 
• 1127735-34-5 C₁₃H₁₃ClO₄ 
• 944154-77-2 lithium 1-(4-chlorophenyl)-4-ethoxy-2-methyl-3,4-dioxobutan-1-olate 
• 192702-54-8 5-(4-chloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 68716-47-2 2,4-dichlorophenylboronic acid 
• 1345698-93-2 4-[1-(4-chlorophenyl)prop-1-en-1-yl]morpholine 
• 869192-36-9 Ethyl 1-(2,4-dichlorophenyl)-4-methyl-5-(((trifluoromethyl)sulphonyl)oxy)-1H-pyrazole-3-carboxylate 

Downstream Products

• 162758-35-2 rimonabant acid 
• 168273-06-1 rimonabant 
• 443141-90-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbohydrazide 
• 614727-40-1 N-(1-hexadecyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1093108-07-6 N-(1-oleyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
• 953758-69-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(4-methylpiperazin-1-yl)-1H-pyrazole-3-carboxamide 
• 1291067-90-7 O-4332 
• 1291067-91-8 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-[3-(N,N-diethylamino) propyl]-1H-pyrazol-3-carboxamide 
• 1291067-92-9 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(4-methylcyclohexyl)-1H-pyrazol-3-carboxamide 
• 1291067-93-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(3-(pyrrolidin-1-yl)propyl)-1H-pyrazole-3-carboxamide 
• 1291067-94-1 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(4-(piperidin-1-yl)butyl)-1H-pyrazole-3-carboxamide 
• 1291067-95-2 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-[2-(7-methoxynaphthalen-2-yl)ethyl]-1H-pyrazol-3-carboxamide 
• 1291068-03-5 [2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methylthio]acetic acid 
• 1291068-04-6 [2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methylthio]propionic acid 

Relevant articles and documents

The structure of two pyrazole esters related to Rimonabant

Two 1,5-diarylpyrazoles related to the antiobesity agent Rimonabant have been synthesized and their structure determined by X-ray crystallography. Compound 2, 1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxy late, forms strange cry

Synthesis of novel pyrazole derivatives incorporating one dicarba-closo-dodecaborane unit

Boron clusters, and especially dicarba-closo-dodecaboranes, can be used as hydrophobic pharmacophores in the design of new drugs. In the current letter, analogs of the CB1 receptor inverse agonist Rimonabant incorporating a carborane cage (either ortho- o

Process for Making Biologically Active Compounds and Intermediates Thereof

A process of manufacturing biologically active compounds, their analogs, pharmaceutically acceptable salts, solvates, polymorphs, isotopic variants, and intermediates thereof. Notably, the compounds of the formula IA, 1B, 1C. 1D. 1E, 1F and IG for which novel processes have been disclosed, selectively act on the cannabinoid receptors, and with high affinity. The processes for the preparation of the compounds enable the syntheses of cannabinoid modulators on a large-scale that are eco-friendly and economically viable. Additionally, the processes disclosed enable the synthesis of cannabinoid modulators with high purity and in high yield for their use in making drug substance and drug products.

MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF

Disclosed are inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.